Skip to content

Elizabeth H.Z. Thompson, EVP, Head of Research & Dev at Acadia Pharmaceuticals, sold ACAD on Jul 30, 2026

Data as of Oct 27

▼ SELL$431K16,508 shares at $26.13Elizabeth H.Z. Thompson EVP, Head of Research & DevACAD Acadia Pharmaceuticals Inc
Watch ACAD
Traded
Jul 30, 2026
Disclosed
Jul 31, 2026
Filed
1 day after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Elizabeth H.Z. Thompson, EVP, Head of Research & Dev at Acadia Pharmaceuticals, sold ACAD on Jul 30, 2026TRADEDDISCLOSED
ACADSimilar stocks (XLV — its sector index fund), rebased to ACAD's price on the disclosure day
ACAD since disclosure
−22.0%
after the sale
Similar stocks (XLV) since disclosure
+10.2%
XLV — its sector index fund

Change in closing price from Jul 31, 2026 (the first trading day on or after disclosure) to Oct 27, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLElizabeth H.Z. Thompson EVP, Head of Research & DevACAD Acadia Pharmaceuticals Inc$1.3Kdisclosed Jul 31 · filed 1 day after the trade

See every trade on ACAD →